3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

ProductInformation

Pristane

Product Number **P 1403**
Store at Room Temperature

Product Description
Molecular Formula: $C_{19}H_{40}$
Molecular Weight: 268.5
CAS Number: 1921-70-6
Density: 0.782 g/ml
Congealing Point: -100 °C[1]

2,6,10,14-Tetrametylpentadecane (Pristane) is used to precondition the peritoneal cavity of mice, prior to the induction of ascites fluid with myeloma cells. Several different protocols have been described in the literature.[2,3,4]

The success rate in tumor development and the probability of ascites formation are increased by intraperitoneal injection of 0.5 ml of Pristane or incomplete Freund's adjuvant a few days prior to injecting the cells.[5,6]

This product is sterile filtered and tested for the absence of endotoxins.

Precautions and Disclaimer
For Laboratory Use Only. Not for drug, household or other uses.

Preparation Instructions
This product is miscible with hexane (10%[v/v]).

Procedure
The suggested method for the use of this product is as follows: Inject about 0.5 ml of Pristane per animal intraperitoneally and wait a minimum of two weeks (up to several months). Follow with injection of the hybridoma cells or ascites fluid from another animal. Allow another 3-4 weeks to see a positive response. If frozen cells are being used for injection, it is important that they are in the log phase of growth prior to injection. The biggest problems arise from rushing the injection schedule. It is critical that the mice are given enough time to respond. In addition, not all hybridomas will grow as ascites tumors.

References
1. The Merck Index, 11th ed., Entry# 7757.
2. Hoogenraad, N. J. and Wraight, C. J., The effect of pristane on ascites tumor formation and monoclonal antibody formation. Methods Enzymol., **121**, 375-381 (1986).
3. Antibodies: A Laboratory Manual, Harlow, E., and Lane, D., eds., Cold Spring Harbor Laboratory (Cold Spring Harbor, NY: 1988), p. 123.
4. Lacy, M. J., and Voss, E. W. Jr., A modified method to induce immune polyclonal ascites fluid in BALB/c mice using Sp2/0-Ag14 cells. J. Immunol. Methods, **87(2)**, 169-177 (1986).
5. Hoogenrad, N., et al., The effect of pre-injection of mice with pristane on ascites tumour formation and monoclonal antibody production. J. Immunol. Methods, **61(3)**, 317-320 (1983).
6. Mueller, U. W., et al., Monoclonal antibody production by hybridoma growth in Freund's adjuvant primed mice. J. Immunol. Methods, **87(2)**, 193-196 (1986).

CMH/RXR 1/03